eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
6/2021
vol. 38
 
Share:
Share:
more
 
 
abstract:
Review paper

Safety and danger of biologic treatments in psoriasis in context of cutaneous T-cell lymphoma (CTCL)

Karol Kołkowski
1
,
Małgorzata Sokołowska-Wojdyło
2

1.
Dermatological Students Scientific Association, Department of Dermatology, Venerology and Allergology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland
2.
Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland
Adv Dermatol Allergol 2021; XXXVIII (6): 953–960
Online publish date: 2021/10/25
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Microenvironment has a significant impact on the pathogenesis of cutaneous T-cell lymphoma (CTCL), especially in the context of new emerging biologic therapies. Our aim was to review the literature on interleukins 12, 17, 23 and tumour necrosis factor-a in mycosis fungoides in order to clarify the safety of using biologics in the treatment of psoriasis. Our analysis suggests that these drugs may have an impact on the progression of CTCL. Concluding, in case of uncertain psoriatic lesions, a biopsy followed by pathologic examination should exclude the possibility of co-existence of a primary cutaneous lymphoma before administration of therapies affecting cytokine profiles.
keywords:

cutaneous T-cell lymphoma, mycosis fungoides, biologic treatment, psoriasis, interleukin-12, interleukin-17, tumour necrosis factor-a

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.